Thats the key right there, like a new IPO but know the data great already, loaded up.
stocktwits also has link
What makes Anavex such an exciting story is the Company is not focused on treating the symptoms of Alzheimer’s but rather is focused on the root cause which is believed to be protein misfolding. AVXL’s Anavex 2-73 can work as an agonist for the sig-1R receptor that is behind protein misfolding. What is even more exciting is the fact that the same mechanism can work in Parkinson’s and Huntington diseases.
AVXL lead drug candidates, Anavex 2-73 and Anavex PLUS, a combination of Anavex 2-73 and donepezil (Aricept®) are currently being evaluated in a Phase 2a clinical trial for Alzheimer’s disease and continue to be the major catalyst here.
In earlier preclinical studies, Anavex 2-73 showed potential to halt and/or reverse Alzheimer’s disease.Additionally, positive preclinical data reveals the potential for Anavex 2-73 as a platform drug to treat additional CNS disorders, including epilepsy.
The Fly On the Wall - Look Up VRX
The Fly On The Wall
Valeant's Philidor gave workers payment boost instructions, WSJ says
Philidor Rx Services, a mail-order pharmacy used by Valeant, told employees to use the identification number of a partner pharmacy to secure payment if a health insurer wouldn't work for it, the Wall StreetJournal reports, citing a Philidor training manual. "We have a couple of different 'back door' approaches to receive payment from the insurance company," the manual reads
The Fly 10:06
Pershing sees more bad press, regulator scrutiny for Valeant in coming months »